Rogaratinib Inhibitor

Name: Rogaratinib Inhibitor; MyBioSource
Brand: MyBioSource
SKU: MBS5755475
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5755475

Rogaratinib is an aberrant inhibitor of fibroblast growth factor receptor (FGFR). Rogaratinib is as an orally available, selective and potent inhibitor of FGFR-1, -2 and -3 kinase activity. More details

Please Inquire

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Online Datasheet in PDF

Product Name

Rogaratinib, Inhibitor

Full Product Name

Rogaratinib

Product Synonym Names

BAY1163877

Form/Format

Solid. Powder

Purity/Purification

98.00%

Preparation and Storage

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

Molecular Weight

466.56

Solubility

DMSO: 5.5mg/mL (11.78mM) Need ultrasonic
(<1mg/ml refers to the product slightly soluble or insoluble)

Formula

C23H26N6O3S

SMILES

COCC1=C(CN2CCNC(=O)C2)N2N=CN=C(N)C2=C1C1=CC2=C(S1)C(OC)=CC(C)=C2

CAS Number

1443530-05-9

Target & IC50

FGFR

Product Categories/Family for Rogaratinib, inhibitor

Angiogenesis; FGFR; Tyrosine Kinase/Adaptors

Product References and Citations for Rogaratinib, inhibitor

Sylvia Grunewald, Oliver Politz, Sebastian Bender,et al.Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models. Int J Cancer. 2019 Sep 1;145(5):1346-1357.
Sylvia Grunewald, Oliver Politz, Sebastian Bender,et al.Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models. Int J Cancer. 2019 Sep 1;145(5):1346-1357.
Kim SM, et al. Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy. Oncogenesis. 2016 Jul 18;5(7):e241.
Kim SM, et al. Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy. Oncogenesis. 2016 Jul 18;5(7):e241.

Other Notes

Small volumes of Rogaratinib, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for Rogaratinib purchase

MBS5755475 is an inhibitor targeting Rogaratinib.